Artificial intelligence aids in development of nanomedicines for cancer management

Ping Tan; Xiaoting Chen; Hu Zhang; Qiang Wei; Kui Luo

doi:10.1016/j.semcancer.2023.01.005

Artificial intelligence aids in development of nanomedicines for cancer management

Semin Cancer Biol. 2023 Feb:89:61-75. doi: 10.1016/j.semcancer.2023.01.005. Epub 2023 Jan 20.

Authors

Ping Tan¹, Xiaoting Chen¹, Hu Zhang², Qiang Wei³, Kui Luo⁴

Affiliations

¹ Department of Urology, and Department of Radiology, Institute of Urology, and Huaxi MR Research Center (HMRRC), Animal Experimental Center, National Clinical Research Center for Geriatrics, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
² Amgen Bioprocessing Centre, Keck Graduate Institute, Claremont, CA 91711, USA.
³ Department of Urology, and Department of Radiology, Institute of Urology, and Huaxi MR Research Center (HMRRC), Animal Experimental Center, National Clinical Research Center for Geriatrics, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: weiqiang@scu.edu.cn.
⁴ Department of Urology, and Department of Radiology, Institute of Urology, and Huaxi MR Research Center (HMRRC), Animal Experimental Center, National Clinical Research Center for Geriatrics, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: luokui@scu.edu.cn.

PMID: 36682438
DOI: 10.1016/j.semcancer.2023.01.005

Abstract

Over the last decade, the nanomedicine has experienced unprecedented development in diagnosis and management of diseases. A number of nanomedicines have been approved in clinical use, which has demonstrated the potential value of clinical transition of nanotechnology-modified medicines from bench to bedside. The application of artificial intelligence (AI) in development of nanotechnology-based products could transform the healthcare sector by realizing acquisition and analysis of large datasets, and tailoring precision nanomedicines for cancer management. AI-enabled nanotechnology could improve the accuracy of molecular profiling and early diagnosis of patients, and optimize the design pipeline of nanomedicines by tuning the properties of nanomedicines, achieving effective drug synergy, and decreasing the nanotoxicity, thereby, enhancing the targetability, personalized dosing and treatment potency of nanomedicines. Herein, the advances in AI-enabled nanomedicines in cancer management are elaborated and their application in diagnosis, monitoring and therapy as well in precision medicine development is discussed.

Keywords: Artificial intelligence; Cancer nanomedicine; Nanomedicine; Nanotechnology; Precision medicine.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Artificial Intelligence
Drug Delivery Systems
Humans
Nanomedicine*
Nanotechnology
Neoplasms* / diagnosis
Neoplasms* / drug therapy